Collaboration and option agreement for cell therapy for cardiovascular applicationCollaboration and Option Agreement • July 22nd, 2024
Contract Type
FiledJuly 22nd, 2024
Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002.